Keystone Nano
 | This article needs additional citations for verification. (August 2015) |
Keystone Nano, founded in 2005, is an American-based company based in Pennsylvania, that creates nanoscale products to diagnose and treat human disease and improve the quality of life.[1]
Patents[edit]
Keystone Nano Inc. and team has been granted the follow patents:
- US Patent (8,747,891) - Awarded to The Penn State Research Foundation and Keystone Nano's Chief Medical Officer Mark Kester, this patent describes the process of loading Ceramide nano-scale liposomes with anti-cancer compounds and create a combination of therapies that benefit from the therapeutic activity of both Ceramide and the anti-cancer compound. This process improves the delivery of both compounds by targeting tumors and extending the time of biological activity.[2][3]
FDA Approval[edit]
In January 2017, the FDA approved the investigational new drug application, NanoLiposome, to assess the product as a form of treatment for solid tumors. Phase 1 trials will take place at the University of Maryland, University of Virginia, and the Medical University of South Carolina.[4]
Compound[edit]
Keystone was approved in 2017 to begin clinical trials to assess ceramide nanoliposome for possible use in treating cancer.[5]
References[edit]
- ^ "Company Overview of Keystone Nano, Inc". Bloomberg. Retrieved 10 August 2015.
- ^ "Patent for the Novel Cancer Therapies – Ceramide Nanoliposomes". Nanotechnology Now. Retrieved 9 August 2015.
- ^ Falce, Lori. "Local firm builds on Penn State patent to fight cancer". Centre Daily Times. Archived from the original on 23 September 2015. Retrieved 10 August 2015.
- ^ "FDA Approves Investigational New Drug Application for Ceramide NanoLiposome". Pharmacy Times. Retrieved 14 January 2017.
- ^ "Investigational cancer compound receives FDA approval to begin human trials". Penn State News.